Clinical Trial: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Study Status: Completed
Recruit Status: RECRUITING
Condition: Solid Tumor, Adult
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent U
Brief Summary:
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A*02 expression.The main questions this study aims to answer are:Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patientsPhase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the…
Read more